The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
4don MSN
Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...
8don MSN
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...
The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and ...
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
The long-running U.S. shortage of Novo Nordisk's blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the Food and Drug Administration said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results